Stroke. 2009;40:e487-e488
Published online before print May 14, 2009,
doi: 10.1161/STROKEAHA.109.547059
(Stroke. 2009;40:e487.)
© 2009 American Heart Association, Inc.
Interventions for Treating Depression After Stroke
Maree L. Hackett, PhD;
Craig S. Anderson, PhD, FRACP, FAFPHM;
Allan O. House, DM, MRCP, MRCPsych
Jun Xia, BA
From the George Institute for International Health (M.L.H., C.S.A.), University of Sydney and Royal Prince Alfred Hospital, Sydney, Australia; the Leeds Institute of Health Sciences (A.O.H.), University of Leeds, UK; and the Cochrane Schizophrenia Group (J.X.), POPE building, Nottingham University, UK.
Correspondence to Maree Hackett, The George Institute for International Health, PO Box M201, Missenden Road, Sydney, NSW 2050, Australia. E-mail mhackett{at}george.org.au
Graeme J. Hankey MD, FRCP Section Editor:
Key Words: depression stroke recovery treatment meta-analysis
 |
Introduction
|
|---|
Depression is an important consequence of stroke, affecting
one third of patients, that often goes undetected or is inadequately
treated and managed. This is an update of a Cochrane review
we first published in 2004 to determine whether pharmacological,
psychological, or electroconvulsive treatment (ECT) of depression
in patients with stroke can improve outcome.
1
 |
Search Strategy
|
|---|
We searched the trials registers of the Cochrane Stroke Group
(last searched October 2007) and the Cochrane Depression Anxiety
and Neurosis Group (last searched February 2008). In addition,
we searched the Cochrane Central Register of Controlled Trials
(
The Cochrane Library, Issue 1, 2008), MEDLINE (1966 to May
2006), EMBASE (1980 to May 2006), CINAHL (1982 to May 2006),
PsycINFO (1967 to May 2006), and other databases. We also searched
reference lists, clinical trials registers, conference proceedings,
and dissertation abstracts and contacted authors, researchers,
and pharmaceutical companies.
 |
Selection Criteria
|
|---|
We considered all truly randomized controlled trials comparing
pharmaceutical agents with placebo, or various forms of psychotherapy
or ECT with standard care (or attention control), to treat depression
in patients with stroke.
 |
Results
|
|---|
We identified 16 trials (17 interventions), with 1655 participants
at entry. Data were available for 13 pharmaceutical trials and
4 trials of psychotherapy. There were no trials of ECT. There
was evidence of benefit of pharmacotherapy in terms of a complete
remission of depression (odds ratio [OR] 0.47, 95% confidence
interval [CI] 0.22 to 0.98) and a reduction (improvement) in
scores on depression rating scales, but there was also evidence
of an increase in adverse events (OR 1.96; 95% CI 1.19 to 3.24).
There was no evidence of benefit of psychotherapy. The analyses
were complicated by the lack of standardized diagnostic and
outcome criteria including multiple measures of depression within
and between trials without a priori identification of the primary
measure, differing analytic methods, with few trials prospectively
recording and reporting adverse events.
 |
Discussion
|
|---|
The addition of 5 new pharmacotherapy trials since 2004 has
altered previous findings to show a small but significant effect
of pharmacotherapy for treating depression and reducing depressive
symptoms after stroke and an associated significant increase
in adverse events. Antidepressants should be used with caution
in people with persistent depressive symptoms after stroke as
little is known about the risks, especially of seizures, falls,
and delirium. More research is required before recommendations
can be made about the routine use of such treatments in light
of the increase in adverse events and a lack of efficacy of
selective serotonin reuptake inhibitors except in those with
severe depression in nonstroke populations.
2 With the addition
of 2 new psychotherapy trials there is still no evidence to
support the use of psychotherapy on its own to treat depression
after stroke.
There is a need for further research using more rigorous methods including concealment of randomization, and blinded treatment allocation and outcome assessments. Future trials to treat depression after stroke should be of adequate power, clearly identify a priori primary and secondary end points, and include prospective assessment and complete reporting of adverse events. Any treatment strategy should be continued for a sufficient duration and follow-up, so that rates of relapse or maintenance of remission can be assessed.
 |
Acknowledgments
|
|---|
We thank the Cochrane Stroke Group, particularly Brenda Thomas,
for searching the Cochrane Stroke Register and assistance with
developing the search strategies. We also thank Hazel Fraser
for assistance throughout the review process.
Sources of Funding
The 2004 published review was supported by a grant from the Stroke Society of Australasia, with additional financial assistance provided by the Academic Unit of Psychiatry, the University of Leeds, and the Department of Clinical Neurosciences, the University of Edinburgh.
Disclosures
During the completion of this work Maree Hackett was in receipt of a National Health and Medical Research Council Public Health (Australia) Fellowship (2006–2009).
Received January 6, 2009;
accepted January 12, 2009.
 |
References
|
|---|
1. Hackett ML, Anderson CS, House AO, Xia J. Interventions for treating depression after stroke.
Cochrane Database of Systematic Reviews. 2008: Issue 2. Art. No.: CD003437. DOI: 003410.001002/14651858.CD14003437.pub14651853.
2. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: A meta-analysis of data submitted to the food and drug administration. PLoS Medicine. 2008; 5: 260–268.